Orexo AB
STO:ORX

Watchlist Manager
Orexo AB Logo
Orexo AB
STO:ORX
Watchlist
Price: 24.3 SEK -0.41%
Market Cap: 843.5m SEK

Orexo AB
Net Change in Cash

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Orexo AB
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
Orexo AB
STO:ORX
Net Change in Cash
-kr9.2m
CAGR 3-Years
73%
CAGR 5-Years
47%
CAGR 10-Years
21%
Calliditas Therapeutics AB
STO:CALTX
Net Change in Cash
-kr68.9m
CAGR 3-Years
55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Net Change in Cash
kr763.4m
CAGR 3-Years
102%
CAGR 5-Years
22%
CAGR 10-Years
21%
E
Enzymatica AB (publ)
STO:ENZY
Net Change in Cash
-kr63.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-4%
S
Swedencare AB (publ)
STO:SECARE
Net Change in Cash
-kr48.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Net Change in Cash
-kr400.5m
CAGR 3-Years
-83%
CAGR 5-Years
-49%
CAGR 10-Years
N/A
No Stocks Found

Orexo AB
Glance View

Market Cap
838.5m SEK
Industry
Pharmaceuticals

Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. The company is headquartered in Uppsala, Uppsala and currently employs 121 full-time employees. The company went IPO on 2005-11-09. The company focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The firm has four commercialized products, several projects developed in partnership, as well as three development programs. The firm's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The firm operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.

ORX Intrinsic Value
35.49 SEK
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Orexo AB's Net Change in Cash?
Net Change in Cash
-9.2m SEK

Based on the financial report for Sep 30, 2025, Orexo AB's Net Change in Cash amounts to -9.2m SEK.

What is Orexo AB's Net Change in Cash growth rate?
Net Change in Cash CAGR 10Y
21%

Over the last year, the Net Change in Cash growth was 87%. The average annual Net Change in Cash growth rates for Orexo AB have been 73% over the past three years , 47% over the past five years , and 21% over the past ten years .

Back to Top